Literature DB >> 30294846

Demographic and clinical features of hidradenitis suppurativa in Korea.

Ji Hoon Yang1, Jungyoon Moon1, Young Chul Kye2, Kwang Joong Kim3, Myeung Nam Kim4, Young Suck Ro5, Mi Youn Park6, Hyo Hyun Ahn2, Mi Woo Lee7, Weon Ju Lee8, Ju Hee Lee9, Jee Bum Lee10, Min Soo Jang11, Yu Sung Choi7, You Won Choi12, Dae Hun Suh1.   

Abstract

Hidradenitis suppurativa (HS) is a chronic, relapsing, inflammatory skin disorder. Although several epidemiological studies have been conducted in Western countries, such data regarding Asian populations are scarce. In this study, we sought to investigate the demographic and clinical features of HS in Korea. A total of 438 patients, diagnosed with HS from May 2007 to April 2017, were enrolled and the electronic medical record of each patient was reviewed. Male patients were predominant with a male : female ratio of 2.5:1. Mean age of disease onset was 23.9 years and most patients had no family history. The most frequently affected area was the buttocks, followed by axillae and groin. Acne and diabetes mellitus were the most prevalent associated diseases and no patients with inflammatory bowel diseases were observed. In the univariable analysis, male patients had severe diseases compared with females with an odds ratio (OR) of 1.790. Two or more affected body regions were associated with HS severity with an OR of 1.693. While involvement of the perineum (OR, 4.067) and buttocks (OR, 1.471) tended to be associated with increased severity of the disease, the inguinal area (OR, 0.620) showed a tendency to be inversely associated with the severity. In multivariable analysis, identified risk factors were the involvement of the perineum (OR, 3.819) and buttocks (OR, 2.288). Smoking status and high body mass index seemed to be associated with more severe diseases. Our results will provide clinical characteristics of HS patients in Asia and help to broaden understanding of HS.
© 2018 Japanese Dermatological Association.

Entities:  

Keywords:  Asia; epidemiology; hidradenitis suppurativa; severity; treatment

Mesh:

Year:  2018        PMID: 30294846     DOI: 10.1111/1346-8138.14656

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  8 in total

Review 1.  Botulinum toxin type A for the management of hidradenitis suppurativa.

Authors:  Huanhuan Qu; Lin Gao
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

Review 2.  Hidradenitis suppurativa.

Authors:  Robert Sabat; Gregor B E Jemec; Łukasz Matusiak; Alexa B Kimball; Errol Prens; Kerstin Wolk
Journal:  Nat Rev Dis Primers       Date:  2020-03-12       Impact factor: 52.329

3.  Questionnaire-based epidemiological study of hidradenitis suppurativa in Japan revealing characteristics different from those in Western countries.

Authors:  Koremasa Hayama; Hideki Fujita; Takashi Hashimoto; Tadashi Terui
Journal:  J Dermatol       Date:  2020-05-22       Impact factor: 4.005

4.  Prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population.

Authors:  Natalia Kirsten; Nicole Zander; Matthias Augustin
Journal:  Arch Dermatol Res       Date:  2020-04-22       Impact factor: 3.017

5.  Characterization of comorbidity heterogeneity among 13,667 patients with hidradenitis suppurativa.

Authors:  Vivian J Hua; James M Kilgour; Hyunje G Cho; Shufeng Li; Kavita Y Sarin
Journal:  JCI Insight       Date:  2021-11-08

6.  Hidradenitis Suppurativa: Estimated Prevalence, Clinical Features, and Risk Factors in Riyadh, Saudi Arabia.

Authors:  Haifa Alsadhan; Abdulrahman I Alfawzan; Amirah Yaqoub; Alyah Almoneef; Mohammad Almohideb
Journal:  Cureus       Date:  2022-03-10

Review 7.  Hidradenitis Suppurativa and 1-Carbon Metabolism: Role of Gut Microbiome, Matrix Metalloproteinases, and Hyperhomocysteinemia.

Authors:  Jack Molnar; Carissa Jo Mallonee; Dragana Stanisic; Rubens P Homme; Akash K George; Mahavir Singh; Suresh C Tyagi
Journal:  Front Immunol       Date:  2020-08-19       Impact factor: 7.561

8.  Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan.

Authors:  Nobukazu Hayashi; Koremasa Hayama; Kenzo Takahashi; Ichiro Kurokawa; Masateru Okazaki; Tomoko Kashiwagi; Eri Iwashita; Tadashi Terui
Journal:  J Dermatol       Date:  2022-01-17       Impact factor: 3.468

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.